In a report released today, Colin Rusch from Oppenheimer reiterated a Buy rating on Amyris (AMRS), with a price target of $9.00. The company’s shares closed last Monday at $4.42.
According to TipRanks.com, Rusch is a top 100 analyst with an average return of 29.6% and a 57.2% success rate. Rusch covers the Industrial Goods sector, focusing on stocks such as American Superconductor, SolarEdge Technologies, and Westport Fuel Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amyris with a $10.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.07 and a one-year low of $1.40. Currently, Amyris has an average volume of 2.61M.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.
